MAKAYLA CARTER: Open Payments
NPI 1194503854 · BOWLING GREEN, KY. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$3,241 in 178 payments from 19 companies in 2025. Trend: 2023 $388 · 2024 $2,740 · 2025 $3,241
Food & beverage: $3,241
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 48 | $762 |
| Janssen Biotech, Inc. | 21 | $348 |
| Takeda Pharmaceuticals U.S.A., Inc. | 13 | $254 |
| Madrigal Pharmaceuticals | 9 | $227 |
| Gilead Sciences, Inc. | 11 | $213 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 12 | $188 |
| Ardelyx, Inc. | 8 | $172 |
| GENZYME CORPORATION | 7 | $165 |
| Phathom Pharmaceuticals, Inc. | 12 | $162 |
| Lilly USA, LLC | 11 | $158 |
Products named: TREMFYA, RINVOQ, DUPIXENT, REZDIFFRA, XIFAXAN, LINZESS, IBSRELA, ENTYVIO.
Industry payments across KY — which companies pay providers there.
